{"transactions":[{"id":42056,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-03T20:27:12.000Z","date":"2024-04-02","kind":"sale","planned":false,"acquired":false,"shares":7000,"price":887.8942,"value":6215259.4,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents weighted average sales price. The shares were sold at prices ranging from $887.57 to $888.32. The Reporting Person will provide upon request, to the Securities and Exchange Commission, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by The Perry & Pena Family Trust, of which Mr. Perry and his wife are co-trustees."}],"balance_after":116000,"source":{"system":"sec-edgar","filing":"0001045810-24-000090","document":"wk-form4_1712176010.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581024000090/wk-form4_1712176010.xml","form_type":"4"}},{"id":44700,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-27T22:06:39.000Z","date":"2024-02-23","kind":"sale","planned":false,"acquired":false,"shares":15000,"price":796.4461,"value":11946691.5,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents weighted average sales price. The shares were sold at prices ranging from $796.00 to $796.77. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by The Perry & Pena Family Trust, of which Mr. Perry and his wife are co-trustees"}],"balance_after":123000,"source":{"system":"sec-edgar","filing":"0001045810-24-000040","document":"wk-form4_1709071584.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581024000040/wk-form4_1709071584.xml","form_type":"4"}},{"id":54749,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-27T22:24:02.000Z","date":"2023-06-23","kind":"grant","planned":false,"acquired":true,"shares":650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Annual grant in connection with service on the Board of Directors. The shares represent restricted stock units that were received as an award, for no consideration. The restricted stock units shall vest as to 50% of the shares on November 15, 2023 and 50% of the shares on May 15, 2024. If the Reporting Person's service as a director terminates at any time due to death, the grant shall immediately become fully vested."}],"balance_after":13612,"source":{"system":"sec-edgar","filing":"0001045810-23-000154","document":"wk-form4_1687904630.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581023000154/wk-form4_1687904630.xml","form_type":"4"}},{"id":55431,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-31T21:15:08.000Z","date":"2023-05-26","kind":"gift","planned":false,"acquired":true,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"The Taylor William Perry 2023 Irrevocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Gift without consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held by The Taylor William Perry 2023 Irrevocable Trust, of which the Reporting Person is a trustee. Mr. Perry disclaims beneficial ownership of the shares held by the trust except to the extent of his pecuniary interest therein, if any."}],"balance_after":1000,"source":{"system":"sec-edgar","filing":"0001045810-23-000099","document":"wk-form4_1685567697.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581023000099/wk-form4_1685567697.xml","form_type":"4"}},{"id":55430,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-31T21:15:08.000Z","date":"2023-05-26","kind":"gift","planned":false,"acquired":true,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"The Zoe Blue Perry 2020 Irrevocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Gift without consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held by The Zoe Blue Perry 2020 Irrevocable Trust, of which the Reporting Person is a trustee. Mr. Perry disclaims beneficial ownership of the shares held by the trust except to the extent of his pecuniary interest therein, if any."}],"balance_after":1000,"source":{"system":"sec-edgar","filing":"0001045810-23-000099","document":"wk-form4_1685567697.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581023000099/wk-form4_1685567697.xml","form_type":"4"}},{"id":55429,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-31T21:15:08.000Z","date":"2023-05-26","kind":"gift","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Gift without consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by The Perry & Pena Family Trust, of which Mr. Perry and his wife are co-trustees"}],"balance_after":138000,"source":{"system":"sec-edgar","filing":"0001045810-23-000099","document":"wk-form4_1685567697.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581023000099/wk-form4_1685567697.xml","form_type":"4"}},{"id":58065,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-28T21:59:05.000Z","date":"2023-02-27","kind":"sale","acquired":false,"shares":1400,"price":237.9968,"value":333195.52,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents weighted average sales price. The shares were sold at prices ranging from $237.79 to $238.32. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by The Perry & Pena Family Trust, of which Mr. Perry and his wife are co-trustees"}],"balance_after":140000,"source":{"system":"sec-edgar","filing":"0001045810-23-000024","document":"wf-form4_167762152866810.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581023000024/wf-form4_167762152866810.xml","form_type":"4"}},{"id":58064,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-28T21:59:05.000Z","date":"2023-02-27","kind":"sale","acquired":false,"shares":5700,"price":237.3644,"value":1352977.08,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents weighted average sales price. The shares were sold at prices ranging from $236.78 to $237.76. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by The Perry & Pena Family Trust, of which Mr. Perry and his wife are co-trustees"}],"balance_after":141400,"source":{"system":"sec-edgar","filing":"0001045810-23-000024","document":"wf-form4_167762152866810.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581023000024/wf-form4_167762152866810.xml","form_type":"4"}},{"id":58063,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-28T21:59:05.000Z","date":"2023-02-27","kind":"sale","acquired":false,"shares":6100,"price":236.2549,"value":1441154.89,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents weighted average sales price. The shares were sold at prices ranging from $235.78 to $236.75. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by The Perry & Pena Family Trust, of which Mr. Perry and his wife are co-trustees"}],"balance_after":147100,"source":{"system":"sec-edgar","filing":"0001045810-23-000024","document":"wf-form4_167762152866810.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581023000024/wf-form4_167762152866810.xml","form_type":"4"}},{"id":58062,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-28T21:59:05.000Z","date":"2023-02-27","kind":"sale","acquired":false,"shares":6800,"price":235.3089,"value":1600100.52,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents weighted average sales price. The shares were sold at prices ranging from $234.78 to $235.76. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by The Perry & Pena Family Trust, of which Mr. Perry and his wife are co-trustees"}],"balance_after":153200,"source":{"system":"sec-edgar","filing":"0001045810-23-000024","document":"wf-form4_167762152866810.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581023000024/wf-form4_167762152866810.xml","form_type":"4"}},{"id":2141122,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T16:21:03.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":5600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":22.3,"underlying":"Common Stock","underlying_shares":5600},"source":{"system":"sec-edgar","filing":"0000899243-22-033162","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924322033162/doc4.xml","form_type":"4"}},{"id":2141121,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T16:21:03.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":5600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":37.09,"underlying":"Common Stock","underlying_shares":5600},"source":{"system":"sec-edgar","filing":"0000899243-22-033162","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924322033162/doc4.xml","form_type":"4"}},{"id":2141120,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T16:21:03.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":5247,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":64.75,"underlying":"Common Stock","underlying_shares":5247},"source":{"system":"sec-edgar","filing":"0000899243-22-033162","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924322033162/doc4.xml","form_type":"4"}},{"id":2141119,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T16:21:03.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":56.3,"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0000899243-22-033162","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924322033162/doc4.xml","form_type":"4"}},{"id":2141118,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T16:21:03.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":42.25,"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-22-033162","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924322033162/doc4.xml","form_type":"4"}},{"id":2141117,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-10-06T16:21:03.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":3600,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit of the Issuer (\"RSU\") represented a contingent right to receive one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3600},"source":{"system":"sec-edgar","filing":"0000899243-22-033162","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924322033162/doc4.xml","form_type":"4"}},{"id":2141116,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-06T16:21:03.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":37865,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation (\"Parent\"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of the effective time of the Merger (the \"Effective Time\") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share (\"Common Stock\"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the \"Merger Consideration\"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-033162","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924322033162/doc4.xml","form_type":"4"}},{"id":2229718,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-06-16T18:38:24.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":3600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":3600,"derivative":{"underlying":"Common Stock","underlying_shares":3600},"source":{"system":"sec-edgar","filing":"0000899243-22-022903","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924322022903/doc4.xml","form_type":"4"}},{"id":2229717,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-16T18:38:24.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":5600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 14, 2022 for 11 months and the remaining 1/12th on the earlier of (i) June 14, 2023 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":5600,"derivative":{"exercise_price":22.3,"expiration_date":"2032-06-13","underlying":"Common Stock","underlying_shares":5600},"source":{"system":"sec-edgar","filing":"0000899243-22-022903","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924322022903/doc4.xml","form_type":"4"}},{"id":2229716,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-06-16T18:38:24.000Z","date":"2022-06-14","kind":"exercise","acquired":false,"shares":3600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vested in a single installment on June 14, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vested in a single installment on June 14, 2022."}],"balance_after":0,"derivative":{"exercise_date":"2022-06-14","underlying":"Common Stock","underlying_shares":3600},"source":{"system":"sec-edgar","filing":"0000899243-22-022903","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924322022903/doc4.xml","form_type":"4"}},{"id":2229715,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-16T18:38:24.000Z","date":"2022-06-14","kind":"exercise","acquired":true,"shares":3600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":37865,"source":{"system":"sec-edgar","filing":"0000899243-22-022903","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924322022903/doc4.xml","form_type":"4"}},{"id":65449,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-07T22:16:20.000Z","date":"2022-06-03","kind":"grant","acquired":true,"shares":1438,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Annual grant in connection with service on the Board of Directors.  The shares represent restricted stock units that were received as an award, for no consideration. The restricted stock units shall vest as to 50% of the shares on November 16, 2022 and 50% of the shares on May 17, 2023. If the Reporting Person's service as a director terminates at any time due to death, the grant shall immediately become fully vested."}],"balance_after":12962,"source":{"system":"sec-edgar","filing":"0001045810-22-000105","document":"wf-form4_165464016506276.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581022000105/wf-form4_165464016506276.xml","form_type":"4"}},{"id":68478,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-21T22:16:31.000Z","date":"2022-03-18","kind":"sale","acquired":false,"shares":100,"price":265.49,"value":26549.0,"ownership":{"direct":true},"balance_after":11524,"source":{"system":"sec-edgar","filing":"0001045810-22-000052","document":"wf-form4_164790097817404.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581022000052/wf-form4_164790097817404.xml","form_type":"4"}},{"id":68477,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-21T22:16:31.000Z","date":"2022-03-18","kind":"sale","acquired":false,"shares":2716,"price":264.92,"value":719522.72,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents weighted average sales price. The shares were sold at prices ranging from $264.43 to $265.36. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":11624,"source":{"system":"sec-edgar","filing":"0001045810-22-000052","document":"wf-form4_164790097817404.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581022000052/wf-form4_164790097817404.xml","form_type":"4"}},{"id":68476,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-21T22:16:31.000Z","date":"2022-03-18","kind":"sale","acquired":false,"shares":12100,"price":263.67,"value":3190407.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents weighted average sales price. The shares were sold at prices ranging from $263.32 to $264.21. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":14340,"source":{"system":"sec-edgar","filing":"0001045810-22-000052","document":"wf-form4_164790097817404.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581022000052/wf-form4_164790097817404.xml","form_type":"4"}},{"id":68475,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-21T22:16:31.000Z","date":"2022-03-18","kind":"sale","acquired":false,"shares":1800,"price":262.9,"value":473220.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents weighted average sales price. The shares were sold at prices ranging from $262.30 to $263.25 The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Adjusted to reflect a four-for-one forward split of the Issuer's common stock in the form of a stock dividend distributed on July 19, 2021 (the \"stock split\")."}],"balance_after":26440,"source":{"system":"sec-edgar","filing":"0001045810-22-000052","document":"wf-form4_164790097817404.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581022000052/wf-form4_164790097817404.xml","form_type":"4"}},{"id":2660492,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-06-21T16:27:25.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":3600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2022 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2022 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":3600,"derivative":{"underlying":"Common Stock","underlying_shares":3600},"source":{"system":"sec-edgar","filing":"0000899243-21-024985","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924321024985/doc4.xml","form_type":"4"}},{"id":2660491,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-21T16:27:25.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":5600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 17, 2021 for 11 months and the remaining 1/12th on the earlier of (i) June 17, 2022 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":5600,"derivative":{"exercise_price":37.09,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":5600},"source":{"system":"sec-edgar","filing":"0000899243-21-024985","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924321024985/doc4.xml","form_type":"4"}},{"id":2660490,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-06-21T16:27:25.000Z","date":"2021-06-17","kind":"exercise","acquired":false,"shares":3037,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vested in a single installment on June 17, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vested in a single installment on June 17, 2021."}],"balance_after":0,"derivative":{"exercise_date":"2021-06-17","underlying":"Common Stock","underlying_shares":3037},"source":{"system":"sec-edgar","filing":"0000899243-21-024985","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924321024985/doc4.xml","form_type":"4"}},{"id":2660489,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-21T16:27:25.000Z","date":"2021-06-17","kind":"exercise","acquired":true,"shares":3037,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":34265,"source":{"system":"sec-edgar","filing":"0000899243-21-024985","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924321024985/doc4.xml","form_type":"4"}},{"id":86161,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-08T20:10:20.000Z","date":"2021-06-04","kind":"grant","acquired":true,"shares":429,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Annual grant in connection with service on the Board of Directors. The shares represent restricted stock units that were received as an award, for no consideration. The restricted stock units shall vest as to 214 of the shares on November 17, 2021 and 215 of the shares on May 18, 2022. If the Reporting Person's service as a director terminates at any time due to death, the grant shall immediately become fully vested."}],"balance_after":7060,"source":{"system":"sec-edgar","filing":"0001045810-21-000092","document":"wf-form4_162318296467604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581021000092/wf-form4_162318296467604.xml","form_type":"4"}},{"id":89988,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-06T20:55:48.000Z","date":"2021-04-05","kind":"sale","acquired":false,"shares":1400,"price":556.98,"value":779772.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents weighted average sales price. The shares were sold at prices ranging from $556.92 to $557.00. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":6631,"source":{"system":"sec-edgar","filing":"0001045810-21-000041","document":"wf-form4_161774248584354.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581021000041/wf-form4_161774248584354.xml","form_type":"4"}},{"id":89987,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-06T20:55:48.000Z","date":"2021-04-05","kind":"sale","acquired":false,"shares":4704,"price":556.46,"value":2617587.84,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents weighted average sales price. The shares were sold at prices ranging from $555.90 to $556.88. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":8031,"source":{"system":"sec-edgar","filing":"0001045810-21-000041","document":"wf-form4_161774248584354.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581021000041/wf-form4_161774248584354.xml","form_type":"4"}},{"id":2972889,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2020-11-19T20:19:50.000Z","date":"2020-11-17","kind":"disposition_to_issuer","acquired":false,"shares":3000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."}],"balance_after":0,"derivative":{"exercise_price":100.27,"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0000899243-20-031755","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320031755/doc4.xml","form_type":"4"}},{"id":2972888,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2020-11-19T20:19:50.000Z","date":"2020-11-17","kind":"disposition_to_issuer","acquired":false,"shares":6600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."}],"balance_after":0,"derivative":{"exercise_price":47.77,"underlying":"Common Stock","underlying_shares":6600},"source":{"system":"sec-edgar","filing":"0000899243-20-031755","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320031755/doc4.xml","form_type":"4"}},{"id":2972887,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2020-11-19T20:19:50.000Z","date":"2020-11-17","kind":"disposition_to_issuer","acquired":false,"shares":11000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."}],"balance_after":0,"derivative":{"exercise_price":48.85,"underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0000899243-20-031755","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320031755/doc4.xml","form_type":"4"}},{"id":2972886,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2020-11-19T20:19:50.000Z","date":"2020-11-17","kind":"disposition_to_issuer","acquired":false,"shares":11000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."}],"balance_after":0,"derivative":{"exercise_price":14,"underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0000899243-20-031755","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320031755/doc4.xml","form_type":"4"}},{"id":2972885,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2020-11-19T20:19:50.000Z","date":"2020-11-17","kind":"disposition_to_issuer","acquired":false,"shares":11000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."}],"balance_after":0,"derivative":{"exercise_price":13.6,"underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0000899243-20-031755","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320031755/doc4.xml","form_type":"4"}},{"id":2972884,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2020-11-19T20:19:50.000Z","date":"2020-11-17","kind":"disposition_to_issuer","acquired":false,"shares":21800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option."}],"balance_after":0,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":21800},"source":{"system":"sec-edgar","filing":"0000899243-20-031755","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320031755/doc4.xml","form_type":"4"}},{"id":2972883,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-19T20:19:50.000Z","date":"2020-11-17","kind":"other","acquired":false,"shares":29508,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company (\"Parent\"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 17, 2020 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"shares","element":"transactionShares","label":"F2","text":"A portion of this amount consists of unvested restricted stock units (\"RSUs\"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company (\"Parent\"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 17, 2020 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"A portion of this amount consists of unvested restricted stock units (\"RSUs\"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-031755","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320031755/doc4.xml","form_type":"4"}},{"id":3101757,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-23T18:25:38.000Z","date":"2020-06-13","kind":"exercise","acquired":false,"shares":2300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"RSUs convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2300},"source":{"system":"sec-edgar","filing":"0000899243-20-017508","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320017508/doc4a.xml","form_type":"4/A","original_submission_date":"2020-06-16"}},{"id":3101756,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-23T18:25:38.000Z","date":"2020-06-13","kind":"exercise","acquired":true,"shares":2300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"RSUs convert into common stock on a one-for-one basis."}],"balance_after":27708,"source":{"system":"sec-edgar","filing":"0000899243-20-017508","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320017508/doc4a.xml","form_type":"4/A","original_submission_date":"2020-06-16"}},{"id":3102928,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-22T18:59:24.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":1800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":1800,"derivative":{"underlying":"Common Stock","underlying_shares":1800},"source":{"system":"sec-edgar","filing":"0000899243-20-017418","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320017418/doc4.xml","form_type":"4"}},{"id":3102927,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-22T18:59:24.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in 12 equal monthly installments after June 18, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":3000,"derivative":{"exercise_price":100.27,"expiration_date":"2030-06-17","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0000899243-20-017418","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320017418/doc4.xml","form_type":"4"}},{"id":3104111,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-19T21:33:43.000Z","date":"2020-06-17","kind":"grant","acquired":true,"shares":3037,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2021 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 17, 2021 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":3037,"derivative":{"underlying":"Common Stock","underlying_shares":3037},"source":{"system":"sec-edgar","filing":"0000899243-20-017318","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320017318/doc4.xml","form_type":"4"}},{"id":3104110,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-19T21:33:43.000Z","date":"2020-06-17","kind":"grant","acquired":true,"shares":5247,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 17, 2020 for 11 months and the remaining 1/12th on the earlier of (i) June 17, 2021 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":5247,"derivative":{"exercise_price":64.75,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":5247},"source":{"system":"sec-edgar","filing":"0000899243-20-017318","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320017318/doc4.xml","form_type":"4"}},{"id":3104109,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-19T21:33:43.000Z","date":"2020-06-17","kind":"exercise","acquired":true,"shares":4800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vested in a single installment on June 17, 2020, the date of the Issuer's annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vested in a single installment on June 17, 2020, the date of the Issuer's annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4800},"source":{"system":"sec-edgar","filing":"0000899243-20-017318","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320017318/doc4.xml","form_type":"4"}},{"id":3104108,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-19T21:33:43.000Z","date":"2020-06-17","kind":"exercise","acquired":true,"shares":4800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":31228,"source":{"system":"sec-edgar","filing":"0000899243-20-017318","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320017318/doc4.xml","form_type":"4"}},{"id":3108666,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-16T18:03:19.000Z","date":"2020-06-13","kind":"exercise","acquired":true,"shares":2300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"RSUs convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2300},"source":{"system":"sec-edgar","filing":"0000899243-20-016682","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320016682/doc4.xml","form_type":"4"}},{"id":3108665,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-16T18:03:19.000Z","date":"2020-06-13","kind":"exercise","acquired":true,"shares":2300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"RSUs convert into common stock on a one-for-one basis."}],"balance_after":27708,"source":{"system":"sec-edgar","filing":"0000899243-20-016682","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320016682/doc4.xml","form_type":"4"}},{"id":103945,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-12T22:21:40.000Z","date":"2020-06-10","kind":"grant","acquired":true,"shares":712,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Annual grant in connection with service on the Board of Directors. The shares represent restricted stock units that were received as an award, for no consideration. The restricted stock units shall vest as to 50% of the shares on November 18, 2020 and 50% of the shares on May 19, 2021. If the Reporting Person's service as a director terminates at any time due to death, the grant shall immediately become fully vested."}],"balance_after":12735,"source":{"system":"sec-edgar","filing":"0001045810-20-000097","document":"wf-form4_159200048375741.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581020000097/wf-form4_159200048375741.xml","form_type":"4"}},{"id":104336,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-29T22:29:14.000Z","date":"2020-05-27","kind":"sale","acquired":false,"shares":600,"price":342.7283,"value":205636.98,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F14","text":"Represents weighted average sales price. The shares were sold at prices ranging from $342.40 to $343.35. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":12023,"source":{"system":"sec-edgar","filing":"0001045810-20-000077","document":"wf-form4_159079133647734.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581020000077/wf-form4_159079133647734.xml","form_type":"4"}},{"id":104335,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-29T22:29:14.000Z","date":"2020-05-27","kind":"sale","acquired":false,"shares":300,"price":341.5433,"value":102462.99,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Represents weighted average sales price. The shares were sold at prices ranging from $341.19 to $341.73. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":12623,"source":{"system":"sec-edgar","filing":"0001045810-20-000077","document":"wf-form4_159079133647734.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581020000077/wf-form4_159079133647734.xml","form_type":"4"}},{"id":104334,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-29T22:29:14.000Z","date":"2020-05-27","kind":"sale","acquired":false,"shares":300,"price":340.3767,"value":102113.01,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents weighted average sales price. The shares were sold at prices ranging from $340.04 to $341.00. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":12923,"source":{"system":"sec-edgar","filing":"0001045810-20-000077","document":"wf-form4_159079133647734.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581020000077/wf-form4_159079133647734.xml","form_type":"4"}},{"id":104333,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-29T22:29:14.000Z","date":"2020-05-27","kind":"sale","acquired":false,"shares":600,"price":339.1567,"value":203494.02,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents weighted average sales price. The shares were sold at prices ranging from $338.65 to $339.61 The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":13223,"source":{"system":"sec-edgar","filing":"0001045810-20-000077","document":"wf-form4_159079133647734.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581020000077/wf-form4_159079133647734.xml","form_type":"4"}},{"id":104332,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-29T22:29:14.000Z","date":"2020-05-27","kind":"sale","acquired":false,"shares":600,"price":338.0933,"value":202855.98,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents weighted average sales price. The shares were sold at prices ranging from $337.57 to $338.51. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":13823,"source":{"system":"sec-edgar","filing":"0001045810-20-000077","document":"wf-form4_159079133647734.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581020000077/wf-form4_159079133647734.xml","form_type":"4"}},{"id":104331,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-29T22:29:14.000Z","date":"2020-05-27","kind":"sale","acquired":false,"shares":800,"price":336.9725,"value":269578.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents weighted average sales price. The shares were sold at prices ranging from $336.54 to $337.49. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":14423,"source":{"system":"sec-edgar","filing":"0001045810-20-000077","document":"wf-form4_159079133647734.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581020000077/wf-form4_159079133647734.xml","form_type":"4"}},{"id":104330,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-29T22:29:14.000Z","date":"2020-05-27","kind":"sale","acquired":false,"shares":1202,"price":335.867,"value":403712.134,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents weighted average sales price. The shares were sold at prices ranging from $335.33 to $336.32. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":15223,"source":{"system":"sec-edgar","filing":"0001045810-20-000077","document":"wf-form4_159079133647734.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581020000077/wf-form4_159079133647734.xml","form_type":"4"}},{"id":104329,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-29T22:29:14.000Z","date":"2020-05-27","kind":"sale","acquired":false,"shares":404,"price":333.4514,"value":134714.3656,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents weighted average sales price. The shares were sold at prices ranging from $333.09 to $333.68. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":16425,"source":{"system":"sec-edgar","filing":"0001045810-20-000077","document":"wf-form4_159079133647734.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581020000077/wf-form4_159079133647734.xml","form_type":"4"}},{"id":104328,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-29T22:29:14.000Z","date":"2020-05-27","kind":"sale","acquired":false,"shares":1100,"price":332.2009,"value":365420.99,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents weighted average sales price. The shares were sold at prices ranging from $331.96 to 332.61. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":16829,"source":{"system":"sec-edgar","filing":"0001045810-20-000077","document":"wf-form4_159079133647734.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581020000077/wf-form4_159079133647734.xml","form_type":"4"}},{"id":104327,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-29T22:29:14.000Z","date":"2020-05-27","kind":"sale","acquired":false,"shares":2200,"price":331.3118,"value":728885.96,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents weighted average sales price. The shares were sold at prices ranging from $330.94 to $331.88. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":17929,"source":{"system":"sec-edgar","filing":"0001045810-20-000077","document":"wf-form4_159079133647734.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581020000077/wf-form4_159079133647734.xml","form_type":"4"}},{"id":104326,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-29T22:29:14.000Z","date":"2020-05-27","kind":"sale","acquired":false,"shares":1600,"price":330.3163,"value":528506.08,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents weighted average sales price. The shares were sold at prices ranging from $329.84 to $330.80. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":20129,"source":{"system":"sec-edgar","filing":"0001045810-20-000077","document":"wf-form4_159079133647734.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581020000077/wf-form4_159079133647734.xml","form_type":"4"}},{"id":104325,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-29T22:29:14.000Z","date":"2020-05-27","kind":"sale","acquired":false,"shares":1300,"price":329.2785,"value":428062.05,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents weighted average sales price. The shares were sold at prices ranging from $328.80 to $329.70. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":21729,"source":{"system":"sec-edgar","filing":"0001045810-20-000077","document":"wf-form4_159079133647734.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581020000077/wf-form4_159079133647734.xml","form_type":"4"}},{"id":104324,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-29T22:29:14.000Z","date":"2020-05-27","kind":"sale","acquired":false,"shares":802,"price":327.9323,"value":263001.7046,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents weighted average sales price. The shares were sold at prices ranging from $327.68 to $328.28. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":23029,"source":{"system":"sec-edgar","filing":"0001045810-20-000077","document":"wf-form4_159079133647734.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581020000077/wf-form4_159079133647734.xml","form_type":"4"}},{"id":104323,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-29T22:29:14.000Z","date":"2020-05-27","kind":"sale","acquired":false,"shares":400,"price":326.5125,"value":130605.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents weighted average sales price. The shares were sold at prices ranging from $326.31 to $326.86. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":23831,"source":{"system":"sec-edgar","filing":"0001045810-20-000077","document":"wf-form4_159079133647734.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581020000077/wf-form4_159079133647734.xml","form_type":"4"}},{"id":3150471,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-13T18:07:47.000Z","date":"2020-05-12","kind":"exercise","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares subject to the option are fully vested."}],"balance_after":0,"derivative":{"exercise_price":28.45,"expiration_date":"2027-06-19","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-20-013017","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320013017/doc4.xml","form_type":"4"}},{"id":3150470,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-13T18:07:47.000Z","date":"2020-05-12","kind":"exercise","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares subject to the option are fully vested."}],"balance_after":0,"derivative":{"exercise_price":18.85,"expiration_date":"2026-06-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-20-013017","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320013017/doc4.xml","form_type":"4"}},{"id":3150469,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-13T18:07:47.000Z","date":"2020-05-12","kind":"exercise","acquired":true,"shares":8600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares subject to the option are fully vested."}],"balance_after":0,"derivative":{"exercise_price":20,"expiration_date":"2025-08-10","underlying":"Common Stock","underlying_shares":8600},"source":{"system":"sec-edgar","filing":"0000899243-20-013017","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320013017/doc4.xml","form_type":"4"}},{"id":3150468,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-13T18:07:47.000Z","date":"2020-05-12","kind":"exercise","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares subject to the option are fully vested."}],"balance_after":0,"derivative":{"exercise_price":20,"expiration_date":"2025-08-10","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-20-013017","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320013017/doc4.xml","form_type":"4"}},{"id":3150467,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-13T18:07:47.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":1295,"price":79.1673,"value":102521.6535,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents weighted average sales price. The shares were sold at prices ranging from $79.16 to $79.18. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":26428,"source":{"system":"sec-edgar","filing":"0000899243-20-013017","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320013017/doc4.xml","form_type":"4"}},{"id":3150466,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-13T18:07:47.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":34698,"price":78.6481,"value":2728931.7738,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents weighted average sales price. The shares were sold at prices ranging from $78.16 to $79.1450. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":27723,"source":{"system":"sec-edgar","filing":"0000899243-20-013017","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320013017/doc4.xml","form_type":"4"}},{"id":3150465,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-13T18:07:47.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":13024,"price":77.7133,"value":1012138.0192,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents weighted average sales price. The shares were sold at prices ranging from $77.16 to $78.01. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":62421,"source":{"system":"sec-edgar","filing":"0000899243-20-013017","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320013017/doc4.xml","form_type":"4"}},{"id":3150464,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-13T18:07:47.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":600,"price":76.2842,"value":45770.52,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents weighted average sales price. The shares were sold at prices ranging from $76.15 to $76.44. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":75445,"source":{"system":"sec-edgar","filing":"0000899243-20-013017","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320013017/doc4.xml","form_type":"4"}},{"id":3150463,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-13T18:07:47.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":1350,"price":75.4322,"value":101833.47,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents weighted average sales price. The shares were sold at prices ranging from $75.13 to $75.88. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":76045,"source":{"system":"sec-edgar","filing":"0000899243-20-013017","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320013017/doc4.xml","form_type":"4"}},{"id":3150462,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-13T18:07:47.000Z","date":"2020-05-12","kind":"sale","acquired":false,"shares":2633,"price":74.0088,"value":194865.1704,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents weighted average sales price. The shares were sold at prices ranging from $73.90 to $74.11. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":77395,"source":{"system":"sec-edgar","filing":"0000899243-20-013017","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320013017/doc4.xml","form_type":"4"}},{"id":3150461,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-13T18:07:47.000Z","date":"2020-05-12","kind":"exercise","acquired":true,"shares":15000,"price":28.45,"value":426750.0,"ownership":{"direct":true},"balance_after":80028,"source":{"system":"sec-edgar","filing":"0000899243-20-013017","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320013017/doc4.xml","form_type":"4"}},{"id":3150460,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-13T18:07:47.000Z","date":"2020-05-12","kind":"exercise","acquired":true,"shares":15000,"price":18.85,"value":282750.0,"ownership":{"direct":true},"balance_after":65028,"source":{"system":"sec-edgar","filing":"0000899243-20-013017","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320013017/doc4.xml","form_type":"4"}},{"id":3150459,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-13T18:07:47.000Z","date":"2020-05-12","kind":"exercise","acquired":true,"shares":8600,"price":20,"value":172000.0,"ownership":{"direct":true},"balance_after":50028,"source":{"system":"sec-edgar","filing":"0000899243-20-013017","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320013017/doc4.xml","form_type":"4"}},{"id":3150458,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-13T18:07:47.000Z","date":"2020-05-12","kind":"exercise","acquired":true,"shares":15000,"price":20,"value":300000.0,"ownership":{"direct":true},"balance_after":41428,"source":{"system":"sec-edgar","filing":"0000899243-20-013017","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924320013017/doc4.xml","form_type":"4"}},{"id":107321,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-20T22:59:44.000Z","date":"2020-02-18","kind":"sale","acquired":false,"shares":200,"price":296.89,"value":59378.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents weighted average sales price. The shares were sold at prices ranging from $296.86 to $296.92. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":24231,"source":{"system":"sec-edgar","filing":"0001045810-20-000024","document":"wf-form4_158223956728478.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581020000024/wf-form4_158223956728478.xml","form_type":"4"}},{"id":107320,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-20T22:59:44.000Z","date":"2020-02-18","kind":"sale","acquired":false,"shares":1459,"price":296.36,"value":432389.24,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents weighted average sales price. The shares were sold at prices ranging from $295.81 to $296.61. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":24431,"source":{"system":"sec-edgar","filing":"0001045810-20-000024","document":"wf-form4_158223956728478.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581020000024/wf-form4_158223956728478.xml","form_type":"4"}},{"id":107319,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-20T22:59:44.000Z","date":"2020-02-18","kind":"sale","acquired":false,"shares":505,"price":295.51,"value":149232.55,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents weighted average sales price. The shares were sold at prices ranging from $294.80 to $295.79. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":25890,"source":{"system":"sec-edgar","filing":"0001045810-20-000024","document":"wf-form4_158223956728478.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581020000024/wf-form4_158223956728478.xml","form_type":"4"}},{"id":107318,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-20T22:59:44.000Z","date":"2020-02-18","kind":"sale","acquired":false,"shares":400,"price":294.19,"value":117676.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents weighted average sales price. The shares were sold at prices ranging from $293.68 to $294.55. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":26395,"source":{"system":"sec-edgar","filing":"0001045810-20-000024","document":"wf-form4_158223956728478.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581020000024/wf-form4_158223956728478.xml","form_type":"4"}},{"id":107317,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-20T22:59:44.000Z","date":"2020-02-18","kind":"sale","acquired":false,"shares":1201,"price":292.99,"value":351880.99,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents weighted average sales price. The shares were sold at prices ranging from $292.50 to $293.40. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":26795,"source":{"system":"sec-edgar","filing":"0001045810-20-000024","document":"wf-form4_158223956728478.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581020000024/wf-form4_158223956728478.xml","form_type":"4"}},{"id":107316,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-20T22:59:44.000Z","date":"2020-02-18","kind":"sale","acquired":false,"shares":615,"price":291.76,"value":179432.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents weighted average sales price. The shares were sold at prices ranging from $291.38 to $292.32. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":27996,"source":{"system":"sec-edgar","filing":"0001045810-20-000024","document":"wf-form4_158223956728478.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581020000024/wf-form4_158223956728478.xml","form_type":"4"}},{"id":107315,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-20T22:59:44.000Z","date":"2020-02-18","kind":"sale","acquired":false,"shares":1302,"price":290.68,"value":378465.36,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents weighted average sales price. The shares were sold at prices ranging from $290.28 to $291.08. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":28611,"source":{"system":"sec-edgar","filing":"0001045810-20-000024","document":"wf-form4_158223956728478.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581020000024/wf-form4_158223956728478.xml","form_type":"4"}},{"id":107314,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-20T22:59:44.000Z","date":"2020-02-18","kind":"sale","acquired":false,"shares":2013,"price":289.68,"value":583125.84,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents weighted average sales price. The shares were sold at prices ranging from $289.23 to $290.22. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":29913,"source":{"system":"sec-edgar","filing":"0001045810-20-000024","document":"wf-form4_158223956728478.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581020000024/wf-form4_158223956728478.xml","form_type":"4"}},{"id":107313,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-20T22:59:44.000Z","date":"2020-02-18","kind":"sale","acquired":false,"shares":1057,"price":288.71,"value":305166.47,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents weighted average sales price. The shares were sold at prices ranging from $288.22 to $289.10. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":31926,"source":{"system":"sec-edgar","filing":"0001045810-20-000024","document":"wf-form4_158223956728478.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581020000024/wf-form4_158223956728478.xml","form_type":"4"}},{"id":3482337,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-06-20T16:01:59.000Z","date":"2019-06-18","kind":"grant","acquired":true,"shares":4800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 18, 2020, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 18, 2020, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the earlier of (i) June 18, 2020, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":4800,"derivative":{"underlying":"Common Stock","underlying_shares":4800},"source":{"system":"sec-edgar","filing":"0000899243-19-017617","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924319017617/doc4.xml","form_type":"4"}},{"id":3482336,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-20T16:01:59.000Z","date":"2019-06-18","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in equal monthly installments over a period of 12 months following June 18, 2019, for 11 months and the remaining 1/12th on the earlier of (i) June 18, 2020 or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Issuer's Board of Directors.  This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":7500,"derivative":{"exercise_price":56.3,"expiration_date":"2029-06-17","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0000899243-19-017617","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924319017617/doc4.xml","form_type":"4"}},{"id":3487481,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-06-17T19:01:43.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":2300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock.  The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors.  The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":2300,"derivative":{"underlying":"Common Stock","underlying_shares":2300},"source":{"system":"sec-edgar","filing":"0000899243-19-017232","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924319017232/doc4.xml","form_type":"4"}},{"id":3487480,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-17T19:01:43.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":6600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in 12 equal monthly installments with the first installment on July 13, 2019, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors.  This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":6600,"derivative":{"exercise_price":47.17,"expiration_date":"2029-06-12","underlying":"Common Stock","underlying_shares":6600},"source":{"system":"sec-edgar","filing":"0000899243-19-017232","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924319017232/doc4.xml","form_type":"4"}},{"id":116326,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-28T22:26:52.000Z","date":"2019-05-23","kind":"grant","acquired":true,"shares":1258,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Annual grant in connection with service on the Board of Directors.  The shares represent restricted stock units that were received as an award, for no consideration. The restricted stock units shall vest as to 50% of the shares on November 20, 2019 and 50% of the shares on May 20, 2020. If the Reporting Person's service as a director terminates at any time due to death, the grant shall immediately become fully vested."}],"balance_after":32983,"source":{"system":"sec-edgar","filing":"0001045810-19-000099","document":"wf-form4_155908239758515.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581019000099/wf-form4_155908239758515.xml","form_type":"4"}},{"id":3884790,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-22T18:22:34.000Z","date":"2018-06-20","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest and become exercisable in 12 equal monthly installments, with the first installment on July 20, 2018, subject to the recipient's continued service on the Issuer's Board of Directors.  This option is subject to accelerated vesting upon a change of control of the Issuer."}],"balance_after":15000,"derivative":{"exercise_price":42.25,"expiration_date":"2028-06-19","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-18-017769","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924318017769/doc4.xml","form_type":"4"}},{"id":3893583,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-14T16:06:30.000Z","date":"2018-06-12","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in 12 equal monthly installments with the first installment on July 12, 2018, such that this option is fully exercisable on June 12, 2019. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the issuer's 2015 Stock Option and Incentive Plan, as amended)."}],"balance_after":11000,"derivative":{"exercise_price":48.85,"expiration_date":"2028-06-11","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0000899243-18-016595","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924318016595/doc4.xml","form_type":"4"}},{"id":128621,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-21T22:36:13.000Z","date":"2018-05-17","kind":"grant","acquired":true,"shares":963,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Annual grant in connection with service on the Board of Directors.  The shares represent restricted stock units that were received as an award, for no consideration. The restricted stock units shall vest as to 50% of the shares on November 21, 2018 and 50% of the shares on May 15, 2019. If the Reporting Person's service as a director terminates at any time due to death, the grant shall immediately become fully vested."}],"balance_after":31725,"source":{"system":"sec-edgar","filing":"0001045810-18-000071","document":"wf-form4_152694216041367.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581018000071/wf-form4_152694216041367.xml","form_type":"4"}},{"id":132697,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-14T00:03:32.000Z","date":"2018-02-12","kind":"sale","acquired":false,"shares":17307,"price":227.9312,"value":3944805.2784,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents weighted average sales price. The shares were sold at prices ranging from $227.50 to $228.39. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":30762,"source":{"system":"sec-edgar","filing":"0001045810-18-000006","document":"wf-form4_151856659697728.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581018000006/wf-form4_151856659697728.xml","form_type":"4"}},{"id":137919,"issuer":{"id":1023,"kind":"organization","name":"NVIDIA CORP","symbol":"NVDA"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-08-16T20:07:20.000Z","date":"2017-08-14","kind":"sale","acquired":false,"shares":16281,"price":162.2363,"value":2641369.2003,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents weighted average sales price. The shares were sold at prices ranging from $162.18 to $162.42. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":48069,"source":{"system":"sec-edgar","filing":"0001045810-17-000119","document":"wf-form4_150291402608402.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1045810/000104581017000119/wf-form4_150291402608402.xml","form_type":"4"}},{"id":4274366,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-06-22T21:50:56.000Z","date":"2017-06-20","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest and become exercisable in 12 equal monthly installments, with the first installment on July 20, 2017, subject to the recipient's continued service on the Issuer's Board of Directors.  This option is subject to accelerated vesting upon a change of control of the Issuer."}],"balance_after":15000,"derivative":{"exercise_price":28.45,"expiration_date":"2027-06-19","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-17-016999","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924317016999/doc4.xml","form_type":"4"}},{"id":4278775,"issuer":{"id":145206,"kind":"organization","name":"MyoKardia, Inc.","symbol":"MYOK"},"owners":[{"id":11385,"kind":"person","name":"PERRY MARK L","position":1,"cik":"0001190270","reported_name":"PERRY MARK L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-16T16:14:59.000Z","date":"2017-06-14","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in 12 equal monthly installments with the first installment on July 14, 2017, such that this option is fully exercisable on June 14, 2018. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the issuer's 2015 Stock Option and Incentive Plan)."}],"balance_after":11000,"derivative":{"exercise_price":14,"expiration_date":"2027-06-13","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0000899243-17-016568","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1190270/000089924317016568/doc4.xml","form_type":"4"}}],"next_cursor":"2017-06-16T16:14:59.000000Z,4278775"}